GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (LSE:AVO) » Definitions » Cash Conversion Cycle

Advanced Oncotherapy (LSE:AVO) Cash Conversion Cycle : 0.00 (As of Jun. 2022)


View and export this data going back to 2006. Start your Free Trial

What is Advanced Oncotherapy Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Advanced Oncotherapy's Days Sales Outstanding for the six months ended in Jun. 2022 was 0.
Advanced Oncotherapy's Days Inventory for the six months ended in Jun. 2022 was 0.
Advanced Oncotherapy's Days Payable for the six months ended in Jun. 2022 was 0.
Therefore, Advanced Oncotherapy's Cash Conversion Cycle (CCC) for the six months ended in Jun. 2022 was 0.00.


Advanced Oncotherapy Cash Conversion Cycle Historical Data

The historical data trend for Advanced Oncotherapy's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy Cash Conversion Cycle Chart

Advanced Oncotherapy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1,035.83 - - -

Advanced Oncotherapy Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Advanced Oncotherapy's Cash Conversion Cycle

For the Medical Devices subindustry, Advanced Oncotherapy's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Oncotherapy's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Advanced Oncotherapy's Cash Conversion Cycle falls into.



Advanced Oncotherapy Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Advanced Oncotherapy's Cash Conversion Cycle for the fiscal year that ended in Dec. 2021 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+0-0
=0.00

Advanced Oncotherapy's Cash Conversion Cycle for the quarter that ended in Jun. 2022 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+0-0
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Oncotherapy  (LSE:AVO) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Advanced Oncotherapy Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Oncotherapy (LSE:AVO) Business Description

Traded in Other Exchanges
N/A
Address
4 Tenterden Street, Third Floor, London, GBR, W1S 1TE
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.